a. h. EKMEKÇİ Et Al. , "DO PARKINSON’xxS PATIENTS WHO HAVE BEEN TRANSFERRED TO DUODOPA AFTER DEEP BRAINSTIMULATION HAVE A SPECIFIC CHARACTERISTIC?," INS 13th World Congress , 2017
EKMEKÇİ, a. h. Et Al. 2017. DO PARKINSON’xxS PATIENTS WHO HAVE BEEN TRANSFERRED TO DUODOPA AFTER DEEP BRAINSTIMULATION HAVE A SPECIFIC CHARACTERISTIC?. INS 13th World Congress .
EKMEKÇİ, a. h., KAPTAN, h., GÜLTEKİN, M., & ÖZTÜRK, Ş., (2017). DO PARKINSON’xxS PATIENTS WHO HAVE BEEN TRANSFERRED TO DUODOPA AFTER DEEP BRAINSTIMULATION HAVE A SPECIFIC CHARACTERISTIC? . INS 13th World Congress
EKMEKÇİ, ahmet Et Al. "DO PARKINSON’xxS PATIENTS WHO HAVE BEEN TRANSFERRED TO DUODOPA AFTER DEEP BRAINSTIMULATION HAVE A SPECIFIC CHARACTERISTIC?," INS 13th World Congress, 2017
EKMEKÇİ, ahmet h. Et Al. "DO PARKINSON’xxS PATIENTS WHO HAVE BEEN TRANSFERRED TO DUODOPA AFTER DEEP BRAINSTIMULATION HAVE A SPECIFIC CHARACTERISTIC?." INS 13th World Congress , 2017
EKMEKÇİ, a. h. Et Al. (2017) . "DO PARKINSON’xxS PATIENTS WHO HAVE BEEN TRANSFERRED TO DUODOPA AFTER DEEP BRAINSTIMULATION HAVE A SPECIFIC CHARACTERISTIC?." INS 13th World Congress .
@conferencepaper{conferencepaper, author={ahmet hakan EKMEKÇİ Et Al. }, title={DO PARKINSON’xxS PATIENTS WHO HAVE BEEN TRANSFERRED TO DUODOPA AFTER DEEP BRAINSTIMULATION HAVE A SPECIFIC CHARACTERISTIC?}, congress name={INS 13th World Congress}, city={}, country={}, year={2017}}